Market Overview:
The global prostate cancer testing market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of prostate cancer, technological advancements in prostate cancer testing, and growing demand for early diagnosis and treatment of prostate cancer. The PSA test segment dominates the global market due to its high adoption rate for screening purposes. Based on application, the global market is segmented into hospital associated labs, independent diagnostic laboratories, cancer research institutes (CRIs), and others.
Product Definition:
Prostate cancer is a disease in which malignant (cancer) cells form in the tissues of the prostate. The prostate is a gland in the male reproductive system that helps make semen. Prostate cancer testing is important because it can help find early signs of cancer so that treatment can begin as soon as possible.
PSA Tests:
PSA tests are used for detecting prostate cancer. It is a blood test that measures the level of PSA in the blood. As per National Cancer Institute, it was estimated that around 1,735,350 new cases of prostate cancer would be diagnosed in 2018 and around 609,640 deaths due to this disease would occur in the U.S.
CTC Tests:
CTC tests are also known as POC (Point of Care) test. It is a diagnostic test that delivers results within 15 to 20 minutes and provides information related to the size, shape, and position of prostate cancer. The CTC or POC testing market is expected to witness lucrative growth over the forecast period owing to factors such as increasing demand for rapid diagnosis with minimum hospital stay, rising prevalence of prostate cancer along with growing adoption by physicians in emerging economies including China & India.
Application Insights:
The hospital associated lab segment dominated the market in 2017. This is owing to a large number of tests that are conducted at hospitals and clinics for various prostate cancer related issues. Increasing awareness about early diagnosis of PCA is also contributing to the growth of this segment. For instance, as per an article published by NCBI in 2015, majority of research studies recommend PSA testing for PCa screening purposes along with other tests such as CTA and DRE. However, there are certain situations where these conventional methods fail to provide accurate results or may even lead to complications so individuals prefer seeking second opinion from an independent diagnostic laboratory which can be costly but offers more clarity regarding treatment options available for prostate cancer patients.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of key players, high adoption rate for advanced diagnostic techniques and government initiatives. For instance, as per an article published in NCBI, from 2014 to 2016, around 1 million men were diagnosed with prostate cancer globally. The diagnosis rate was highest in North America followed by Europe due to higher population density and better healthcare facilities compared to other regions.
Asia Pacific is expected to grow at a lucrative CAGR during the forecast period owing to improving healthcare infrastructure coupled with rising awareness about early detection of diseases among people living in this region especially India & China along with growing economy & population which will boost demand for testing products over next eight years till 2030 time frame. Moreover, increasing cases of prostate cancer are also contributing towards regional growth since most countries have started their PSA or CTC screening programs based on TNM classification system developed by American Cancer Society (ACS).
Growth Factors:
- Increasing incidence of prostate cancer
- Growing awareness about prostate cancer and its early detection methods
- Rising demand for better and more accurate diagnostic tests for prostate cancer
- Technological advancements in prostate cancer testing procedures
- Growing number of aging men who are at a higher risk of developing prostate cancer
Scope Of The Report
Report Attributes
Report Details
Report Title
Prostate Cancer Testing Market Research Report
By Type
PSA Tests, CTC Tests, Immunohistochemistry, PCA3 Tests, Others
By Application
Hospital Associated Labs, Independent Diagnostic Laboratories, Cancer Research Institutes, Others
By Companies
Genomic Health, OPKO, Siemens Healthcare, DiaSorin, bioMeriux, Roche, MDx Health, Beckman Coulter, Myriad Genetics, Ambry Genetics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
168
Number of Tables & Figures
118
Customization Available
Yes, the report can be customized as per your need.
Global Prostate Cancer Testing Market Report Segments:
The global Prostate Cancer Testing market is segmented on the basis of:
Types
PSA Tests, CTC Tests, Immunohistochemistry, PCA3 Tests, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Associated Labs, Independent Diagnostic Laboratories, Cancer Research Institutes, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Genomic Health
- OPKO
- Siemens Healthcare
- DiaSorin
- bioMeriux
- Roche
- MDx Health
- Beckman Coulter
- Myriad Genetics
- Ambry Genetics
Highlights of The Prostate Cancer Testing Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- PSA Tests
- CTC Tests
- Immunohistochemistry
- PCA3 Tests
- Others
- By Application:
- Hospital Associated Labs
- Independent Diagnostic Laboratories
- Cancer Research Institutes
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Prostate Cancer Testing Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Prostate cancer testing is a process by which a doctor can determine if you have prostate cancer. Prostate cancer testing may include a physical exam, blood tests, and imaging tests.
Some of the major players in the prostate cancer testing market are Genomic Health, OPKO, Siemens Healthcare, DiaSorin, bioMeriux, Roche, MDx Health, Beckman Coulter, Myriad Genetics, Ambry Genetics.
The prostate cancer testing market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Prostate Cancer Testing Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Prostate Cancer Testing Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Prostate Cancer Testing Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Prostate Cancer Testing Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Prostate Cancer Testing Market Size & Forecast, 2018-2028
4.5.1 Prostate Cancer Testing Market Size and Y-o-Y Growth
4.5.2 Prostate Cancer Testing Market Absolute $ Opportunity
Chapter 5 Global Prostate Cancer Testing Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Prostate Cancer Testing Market Size Forecast by Type
5.2.1 PSA Tests
5.2.2 CTC Tests
5.2.3 Immunohistochemistry
5.2.4 PCA3 Tests
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Prostate Cancer Testing Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Prostate Cancer Testing Market Size Forecast by Applications
6.2.1 Hospital Associated Labs
6.2.2 Independent Diagnostic Laboratories
6.2.3 Cancer Research Institutes
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Prostate Cancer Testing Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Prostate Cancer Testing Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Prostate Cancer Testing Analysis and Forecast
9.1 Introduction
9.2 North America Prostate Cancer Testing Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Prostate Cancer Testing Market Size Forecast by Type
9.6.1 PSA Tests
9.6.2 CTC Tests
9.6.3 Immunohistochemistry
9.6.4 PCA3 Tests
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Prostate Cancer Testing Market Size Forecast by Applications
9.10.1 Hospital Associated Labs
9.10.2 Independent Diagnostic Laboratories
9.10.3 Cancer Research Institutes
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Prostate Cancer Testing Analysis and Forecast
10.1 Introduction
10.2 Europe Prostate Cancer Testing Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Prostate Cancer Testing Market Size Forecast by Type
10.6.1 PSA Tests
10.6.2 CTC Tests
10.6.3 Immunohistochemistry
10.6.4 PCA3 Tests
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Prostate Cancer Testing Market Size Forecast by Applications
10.10.1 Hospital Associated Labs
10.10.2 Independent Diagnostic Laboratories
10.10.3 Cancer Research Institutes
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Prostate Cancer Testing Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Prostate Cancer Testing Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Prostate Cancer Testing Market Size Forecast by Type
11.6.1 PSA Tests
11.6.2 CTC Tests
11.6.3 Immunohistochemistry
11.6.4 PCA3 Tests
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Prostate Cancer Testing Market Size Forecast by Applications
11.10.1 Hospital Associated Labs
11.10.2 Independent Diagnostic Laboratories
11.10.3 Cancer Research Institutes
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Prostate Cancer Testing Analysis and Forecast
12.1 Introduction
12.2 Latin America Prostate Cancer Testing Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Prostate Cancer Testing Market Size Forecast by Type
12.6.1 PSA Tests
12.6.2 CTC Tests
12.6.3 Immunohistochemistry
12.6.4 PCA3 Tests
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Prostate Cancer Testing Market Size Forecast by Applications
12.10.1 Hospital Associated Labs
12.10.2 Independent Diagnostic Laboratories
12.10.3 Cancer Research Institutes
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Prostate Cancer Testing Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Prostate Cancer Testing Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Prostate Cancer Testing Market Size Forecast by Type
13.6.1 PSA Tests
13.6.2 CTC Tests
13.6.3 Immunohistochemistry
13.6.4 PCA3 Tests
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Prostate Cancer Testing Market Size Forecast by Applications
13.10.1 Hospital Associated Labs
13.10.2 Independent Diagnostic Laboratories
13.10.3 Cancer Research Institutes
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Prostate Cancer Testing Market: Competitive Dashboard
14.2 Global Prostate Cancer Testing Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Genomic Health
14.3.2 OPKO
14.3.3 Siemens Healthcare
14.3.4 DiaSorin
14.3.5 bioMeriux
14.3.6 Roche
14.3.7 MDx Health
14.3.8 Beckman Coulter
14.3.9 Myriad Genetics
14.3.10 Ambry Genetics
